Troy Wilson has served as the Executive Chairman of Abintus since October 2020. Troy is a serial entrepreneur with a passion for building exceptional companies that create significant value for employees, investors and most importantly, patients. He currently serves as President, Chief Executive Officer and Chairman of Kura Oncology, Inc. (NASDAQ: KURA) and as President, CEO and Executive Chairman of Wellspring Biosciences LLC, and is the sole managing member of its parent company Araxes Pharma LLC. He also serves as the Chairman of Avidity Biosciences, Inc. (NASDAQ: RNA) where he previously served as the company’s President, Chief Executive Officer and Executive Chairman. Troy is a member of the board of directors of Puma Biotechnology, Inc. (NASDAQ: PBYI). Previously, Troy was the President and Chief Executive Officer and a member of the board of directors of Intellikine, Inc., until its acquisition by Takeda Pharmaceuticals. He holds a J.D. from New York University and graduated with a Ph.D. in bioorganic chemistry and a B.A. in biophysics from UC Berkeley.